Test–retest reliability of the novel 5-HT1B receptor PET radioligand [11C]P943

Aybala Saricicek, Jason Chen, Beata Planeta, Barbara Ruf, Kalyani Subramanyam, Kathleen Maloney, David Matuskey, David Labaree, Lorenz Deserno, Alexander Neumeister, John H. Krystal, Jean Dominique Gallezot, Yiyun Huang, Richard E. Carson, Zubin Bhagwagar

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: [11C]P943 is a novel, highly selective 5-HT1B PET radioligand. The aim of this study was to determine the test–retest reliability of [11C]P943 using two different modeling methods and to perform a power analysis with each quantification technique. Methods: Seven healthy volunteers underwent two PET scans on the same day. Regions of interest (ROIs) were the amygdala, hippocampus, pallidum, putamen, insula, frontal, anterior cingulate, parietal, temporal and occipital cortices, and cerebellum. Two multilinear radioligand quantification techniques were used to estimate binding potential: MA1, using arterial input function data, and the second version of the multilinear reference tissue model analysis (MRTM2), using the cerebellum as the reference region. Between-scan percent variability and intraclass correlation coefficients (ICC) were used to assess test–retest reliability. We also performed power analyses to determine the method that would allow the least number of subjects using within-subject or between-subject study designs. A voxel-wise ICC analysis for MRTM2 BPND was performed for the whole brain and all the ROIs studied. Results: Mean percent variability between two scans across regions ranged between 0.4 % and 12.4 % for MA1 BPND, 0.5 % and 11.5 % for MA1 BPP, 16.7 % and 28.3 % for MA1 BPF, and between 0.2 % and 5.4 % for MRTM2 BPND. The power analyses showed a greater number of subjects were required using MA1 BPF compared with other outcome measures for both within-subject and between-subject study designs. ICC values were the highest using MRTM2 BPND and the lowest with MA1 BPF in ten ROIs. Small regions and regions with low binding had lower ICC values than large regions and regions with high binding. Conclusion: Reliable measures of 5-HT1B receptor binding can be obtained using the novel PET radioligand [11C]P943. Quantification of 5-HT1B receptor binding with MRTM2 BPND and with MA1 BPP provided the least variability and optimal power for within-subject and between-subject designs.

Original languageEnglish (US)
Pages (from-to)468-477
Number of pages10
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume42
Issue number3
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Receptor, Serotonin, 5-HT1B
Cerebellum
Occipital Lobe
Globus Pallidus
Somatosensory Cortex
Putamen
Gyrus Cinguli
Temporal Lobe
Amygdala
Positron-Emission Tomography
Hippocampus
Healthy Volunteers
Outcome Assessment (Health Care)
Brain

Keywords

  • 5-HT
  • Graphical analysis
  • Positron emission tomography
  • Serotonin

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Test–retest reliability of the novel 5-HT1B receptor PET radioligand [11C]P943. / Saricicek, Aybala; Chen, Jason; Planeta, Beata; Ruf, Barbara; Subramanyam, Kalyani; Maloney, Kathleen; Matuskey, David; Labaree, David; Deserno, Lorenz; Neumeister, Alexander; Krystal, John H.; Gallezot, Jean Dominique; Huang, Yiyun; Carson, Richard E.; Bhagwagar, Zubin.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 42, No. 3, 01.01.2015, p. 468-477.

Research output: Contribution to journalArticle

Saricicek, A, Chen, J, Planeta, B, Ruf, B, Subramanyam, K, Maloney, K, Matuskey, D, Labaree, D, Deserno, L, Neumeister, A, Krystal, JH, Gallezot, JD, Huang, Y, Carson, RE & Bhagwagar, Z 2015, 'Test–retest reliability of the novel 5-HT1B receptor PET radioligand [11C]P943', European Journal of Nuclear Medicine and Molecular Imaging, vol. 42, no. 3, pp. 468-477. https://doi.org/10.1007/s00259-014-2958-5
Saricicek, Aybala ; Chen, Jason ; Planeta, Beata ; Ruf, Barbara ; Subramanyam, Kalyani ; Maloney, Kathleen ; Matuskey, David ; Labaree, David ; Deserno, Lorenz ; Neumeister, Alexander ; Krystal, John H. ; Gallezot, Jean Dominique ; Huang, Yiyun ; Carson, Richard E. ; Bhagwagar, Zubin. / Test–retest reliability of the novel 5-HT1B receptor PET radioligand [11C]P943. In: European Journal of Nuclear Medicine and Molecular Imaging. 2015 ; Vol. 42, No. 3. pp. 468-477.
@article{c36ec39250f54e10b09b1ab65d002850,
title = "Test–retest reliability of the novel 5-HT1B receptor PET radioligand [11C]P943",
abstract = "Purpose: [11C]P943 is a novel, highly selective 5-HT1B PET radioligand. The aim of this study was to determine the test–retest reliability of [11C]P943 using two different modeling methods and to perform a power analysis with each quantification technique. Methods: Seven healthy volunteers underwent two PET scans on the same day. Regions of interest (ROIs) were the amygdala, hippocampus, pallidum, putamen, insula, frontal, anterior cingulate, parietal, temporal and occipital cortices, and cerebellum. Two multilinear radioligand quantification techniques were used to estimate binding potential: MA1, using arterial input function data, and the second version of the multilinear reference tissue model analysis (MRTM2), using the cerebellum as the reference region. Between-scan percent variability and intraclass correlation coefficients (ICC) were used to assess test–retest reliability. We also performed power analyses to determine the method that would allow the least number of subjects using within-subject or between-subject study designs. A voxel-wise ICC analysis for MRTM2 BPND was performed for the whole brain and all the ROIs studied. Results: Mean percent variability between two scans across regions ranged between 0.4 {\%} and 12.4 {\%} for MA1 BPND, 0.5 {\%} and 11.5 {\%} for MA1 BPP, 16.7 {\%} and 28.3 {\%} for MA1 BPF, and between 0.2 {\%} and 5.4 {\%} for MRTM2 BPND. The power analyses showed a greater number of subjects were required using MA1 BPF compared with other outcome measures for both within-subject and between-subject study designs. ICC values were the highest using MRTM2 BPND and the lowest with MA1 BPF in ten ROIs. Small regions and regions with low binding had lower ICC values than large regions and regions with high binding. Conclusion: Reliable measures of 5-HT1B receptor binding can be obtained using the novel PET radioligand [11C]P943. Quantification of 5-HT1B receptor binding with MRTM2 BPND and with MA1 BPP provided the least variability and optimal power for within-subject and between-subject designs.",
keywords = "5-HT, Graphical analysis, Positron emission tomography, Serotonin",
author = "Aybala Saricicek and Jason Chen and Beata Planeta and Barbara Ruf and Kalyani Subramanyam and Kathleen Maloney and David Matuskey and David Labaree and Lorenz Deserno and Alexander Neumeister and Krystal, {John H.} and Gallezot, {Jean Dominique} and Yiyun Huang and Carson, {Richard E.} and Zubin Bhagwagar",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/s00259-014-2958-5",
language = "English (US)",
volume = "42",
pages = "468--477",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Test–retest reliability of the novel 5-HT1B receptor PET radioligand [11C]P943

AU - Saricicek, Aybala

AU - Chen, Jason

AU - Planeta, Beata

AU - Ruf, Barbara

AU - Subramanyam, Kalyani

AU - Maloney, Kathleen

AU - Matuskey, David

AU - Labaree, David

AU - Deserno, Lorenz

AU - Neumeister, Alexander

AU - Krystal, John H.

AU - Gallezot, Jean Dominique

AU - Huang, Yiyun

AU - Carson, Richard E.

AU - Bhagwagar, Zubin

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose: [11C]P943 is a novel, highly selective 5-HT1B PET radioligand. The aim of this study was to determine the test–retest reliability of [11C]P943 using two different modeling methods and to perform a power analysis with each quantification technique. Methods: Seven healthy volunteers underwent two PET scans on the same day. Regions of interest (ROIs) were the amygdala, hippocampus, pallidum, putamen, insula, frontal, anterior cingulate, parietal, temporal and occipital cortices, and cerebellum. Two multilinear radioligand quantification techniques were used to estimate binding potential: MA1, using arterial input function data, and the second version of the multilinear reference tissue model analysis (MRTM2), using the cerebellum as the reference region. Between-scan percent variability and intraclass correlation coefficients (ICC) were used to assess test–retest reliability. We also performed power analyses to determine the method that would allow the least number of subjects using within-subject or between-subject study designs. A voxel-wise ICC analysis for MRTM2 BPND was performed for the whole brain and all the ROIs studied. Results: Mean percent variability between two scans across regions ranged between 0.4 % and 12.4 % for MA1 BPND, 0.5 % and 11.5 % for MA1 BPP, 16.7 % and 28.3 % for MA1 BPF, and between 0.2 % and 5.4 % for MRTM2 BPND. The power analyses showed a greater number of subjects were required using MA1 BPF compared with other outcome measures for both within-subject and between-subject study designs. ICC values were the highest using MRTM2 BPND and the lowest with MA1 BPF in ten ROIs. Small regions and regions with low binding had lower ICC values than large regions and regions with high binding. Conclusion: Reliable measures of 5-HT1B receptor binding can be obtained using the novel PET radioligand [11C]P943. Quantification of 5-HT1B receptor binding with MRTM2 BPND and with MA1 BPP provided the least variability and optimal power for within-subject and between-subject designs.

AB - Purpose: [11C]P943 is a novel, highly selective 5-HT1B PET radioligand. The aim of this study was to determine the test–retest reliability of [11C]P943 using two different modeling methods and to perform a power analysis with each quantification technique. Methods: Seven healthy volunteers underwent two PET scans on the same day. Regions of interest (ROIs) were the amygdala, hippocampus, pallidum, putamen, insula, frontal, anterior cingulate, parietal, temporal and occipital cortices, and cerebellum. Two multilinear radioligand quantification techniques were used to estimate binding potential: MA1, using arterial input function data, and the second version of the multilinear reference tissue model analysis (MRTM2), using the cerebellum as the reference region. Between-scan percent variability and intraclass correlation coefficients (ICC) were used to assess test–retest reliability. We also performed power analyses to determine the method that would allow the least number of subjects using within-subject or between-subject study designs. A voxel-wise ICC analysis for MRTM2 BPND was performed for the whole brain and all the ROIs studied. Results: Mean percent variability between two scans across regions ranged between 0.4 % and 12.4 % for MA1 BPND, 0.5 % and 11.5 % for MA1 BPP, 16.7 % and 28.3 % for MA1 BPF, and between 0.2 % and 5.4 % for MRTM2 BPND. The power analyses showed a greater number of subjects were required using MA1 BPF compared with other outcome measures for both within-subject and between-subject study designs. ICC values were the highest using MRTM2 BPND and the lowest with MA1 BPF in ten ROIs. Small regions and regions with low binding had lower ICC values than large regions and regions with high binding. Conclusion: Reliable measures of 5-HT1B receptor binding can be obtained using the novel PET radioligand [11C]P943. Quantification of 5-HT1B receptor binding with MRTM2 BPND and with MA1 BPP provided the least variability and optimal power for within-subject and between-subject designs.

KW - 5-HT

KW - Graphical analysis

KW - Positron emission tomography

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=84925541545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925541545&partnerID=8YFLogxK

U2 - 10.1007/s00259-014-2958-5

DO - 10.1007/s00259-014-2958-5

M3 - Article

C2 - 25427881

AN - SCOPUS:84925541545

VL - 42

SP - 468

EP - 477

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 3

ER -